Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 309 000 KRW 4.04% Market Closed
Market Cap: 16.5T KRW
Have any thoughts about
Alteogen Inc?
Write Note

Alteogen Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Alteogen Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Alteogen Inc
KOSDAQ:196170
Other Long-Term Assets
â‚©1.3B
CAGR 3-Years
475%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Other Long-Term Assets
â‚©143.9B
CAGR 3-Years
36%
CAGR 5-Years
26%
CAGR 10-Years
21%
SK Bioscience Co Ltd
KRX:302440
Other Long-Term Assets
â‚©88.3B
CAGR 3-Years
62%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Other Long-Term Assets
â‚©69.5B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
24%
H
Hugel Inc
KOSDAQ:145020
Other Long-Term Assets
â‚©31.1B
CAGR 3-Years
39%
CAGR 5-Years
34%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Other Long-Term Assets
â‚©9.8B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
N/A
No Stocks Found

Alteogen Inc
Glance View

Market Cap
16.4T KRW
Industry
Biotechnology

Alteogen Inc. is a biopharmaceutical company based in South Korea that has carved out a niche in the development of innovative drug delivery systems. Founded in 2005, the company specializes in the creation of biosimilars and biobetters – biologic drugs that improve upon existing therapies. With a strong pipeline aimed at addressing critical unmet medical needs, Alteogen focuses on therapeutic areas such as oncology, autoimmune diseases, and chronic conditions. One of their standout innovations is the proprietary technology for enhanced antibody-drug conjugates, which can significantly improve the efficacy and safety profiles of existing treatments. As the global demand for advanced therapeutics continues to rise, Alteogen presents a compelling story of potential growth driven by scientific innovation. For investors, Alteogen’s strategic partnerships and collaboration with major pharmaceutical companies amplify its growth trajectory. The company is not only positioned to benefit from its proprietary technologies but is also shaping its portfolio to align with the growing market for biosimilars. As competition in the biopharmaceutical space intensifies, Alteogen’s commitment to research and development sets it apart, showcasing its dedication to delivering next-generation medicines. With a robust clinical development pipeline and strong market momentum, Alteogen Inc. represents an intriguing opportunity for investors looking to tap into the evolution of healthcare and the future of targeted therapies.

Intrinsic Value
33 513.79 KRW
Overvaluation 89%
Intrinsic Value
Price

See Also

What is Alteogen Inc's Other Long-Term Assets?
Other Long-Term Assets
1.3B KRW

Based on the financial report for Sep 30, 2024, Alteogen Inc's Other Long-Term Assets amounts to 1.3B KRW.

What is Alteogen Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
24%

Over the last year, the Other Long-Term Assets growth was -41%. The average annual Other Long-Term Assets growth rates for Alteogen Inc have been 475% over the past three years , 24% over the past five years .

Back to Top